Applications and advances of desensitizing therapeutic agents in pre-sensitized renal transplantation
10.3760/cma.j.cn421203-20231028-00145
- VernacularTitle:脱敏治疗药物在预致敏肾移植中的应用及进展
- Author:
Jiating WANG
1
;
Yuting HU
;
Jie DING
;
Zhangfei SHOU
Author Information
1. 浙江大学医学院，杭州 310030
- Keywords:
Presensitisation;
Kidney transplantation;
Desensitisation treatment
- From:
Chinese Journal of Organ Transplantation
2024;45(3):188-193
- CountryChina
- Language:Chinese
-
Abstract:
Kidney transplantation (KT) is one primary treatment of end-stage renal disease (ESRD). As reported by different centers, 10-year survival rate of transplanted kidneys fluctuates from 75% to 80%. Capable of reducing all-cause mortality in renal failure, KT can significantly improve survival rate and quality-of-life of ESRD patients. The risk of post-transplant rejection is much higher in pre-sensitised recipients than in non-sensitised ones due to the pre-existing anti-human leukocyte antigen antibodies. However, with a rapid development of various desensitisation techniques, transplantation rate and postoperative human/kidney survival rate of recipients have been greatly enhanced. And presensitisation is no longer a contraindication to KT. This review focused upon the latest advances in desensitisation therapeutic agents for pre-sensitised KT.
